Similar articles for PMID: 20506355

Year	Number of Results
2001	1
2002	1
2003	1
2004	1
2005	2
2006	12
2007	7
2008	10
2009	10
2010	12
2011	11
2012	4
2013	5
2014	7
2015	3
2016	8
2017	9
2018	8
2019	7
2020	11
2021	10
2022	6
2023	3
2024	0

1

Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.

Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, Matucci Cerinic M, Riemekasten G, Emery P, Chadha-Boreham H, Charef P, Roux S, Black CM. Seibold JR, et al. Arthritis Rheum. 2010 Jul;62(7):2101-8. doi: 10.1002/art.27466. Arthritis Rheum. 2010. PMID: 20506355 Free article. Clinical Trial.

2

Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.

Furuya Y, Kuwana M. Furuya Y, et al. J Rheumatol. 2011 Oct;38(10):2186-92. doi: 10.3899/jrheum.110499. Epub 2011 Sep 1. J Rheumatol. 2011. PMID: 21885489

3

BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.

King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G. King TE Jr, et al. Am J Respir Crit Care Med. 2008 Jan 1;177(1):75-81. doi: 10.1164/rccm.200705-732OC. Epub 2007 Sep 27. Am J Respir Crit Care Med. 2008. PMID: 17901413 Clinical Trial.

4

Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.

Naidu GSRSNK, Sharma SK, Adarsh MB, Dhir V, Sinha A, Dhooria S, Jain S. Naidu GSRSNK, et al. Rheumatol Int. 2020 Feb;40(2):207-216. doi: 10.1007/s00296-019-04481-8. Epub 2019 Dec 7. Rheumatol Int. 2020. PMID: 31813058 Clinical Trial.

5

Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.

Chauvelot L, Gamondes D, Berthiller J, Nieves A, Renard S, Catella-Chatron J, Ahmad K, Bertoletti L, Camara B, Gomez E, Launay D, Montani D, Mornex JF, Prévot G, Sanchez O, Schott AM, Subtil F, Traclet J, Turquier S, Zeghmar S, Habib G, Reynaud-Gaubert M, Humbert M, Cottin V. Chauvelot L, et al. Arthritis Rheumatol. 2021 Feb;73(2):295-304. doi: 10.1002/art.41512. Epub 2020 Dec 29. Arthritis Rheumatol. 2021. PMID: 32892515

6

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.

Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Galiè N, et al. Circulation. 2006 Jul 4;114(1):48-54. doi: 10.1161/CIRCULATIONAHA.106.630715. Epub 2006 Jun 26. Circulation. 2006. PMID: 16801459 Clinical Trial.

7

Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

Denton CP, Humbert M, Rubin L, Black CM. Denton CP, et al. Ann Rheum Dis. 2006 Oct;65(10):1336-40. doi: 10.1136/ard.2005.048967. Epub 2006 Jun 22. Ann Rheum Dis. 2006. PMID: 16793845 Free PMC article. Clinical Trial.

8

BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.

King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J. King TE Jr, et al. Am J Respir Crit Care Med. 2011 Jul 1;184(1):92-9. doi: 10.1164/rccm.201011-1874OC. Epub 2011 Apr 7. Am J Respir Crit Care Med. 2011. PMID: 21474646 Clinical Trial.

9

Bosentan therapy for pulmonary arterial hypertension.

Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Rubin LJ, et al. N Engl J Med. 2002 Mar 21;346(12):896-903. doi: 10.1056/NEJMoa012212. N Engl J Med. 2002. PMID: 11907289 Free article. Clinical Trial.

10

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.

Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ. Channick RN, et al. Lancet. 2001 Oct 6;358(9288):1119-23. doi: 10.1016/S0140-6736(01)06250-X. Lancet. 2001. PMID: 11597664 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

124 results

Results by year